Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
SciSparc Ltd. - Ordinary Shares
(NQ:
SPRC
)
0.4987
-0.0303 (-5.73%)
Streaming Delayed Price
Updated: 3:58 PM EST, Feb 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about SciSparc Ltd. - Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico
February 04, 2025
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
January 15, 2025
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles
January 13, 2025
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results
January 07, 2025
From
SciSparc Ltd
Via
GlobeNewswire
Nasdaq Surges Over 200 Points; BioLineRx Shares Plummet
January 06, 2025
Via
Benzinga
S&P Jumps 1%; Regional Health Properties Shares Spike Higher
January 06, 2025
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Is Psychedelic-SciSparc Stock Trading Higher On Monday?
January 06, 2025
SciSparc teams up with Clearmind Medicine on innovative therapies for binge behaviors and secures FDA approval for a Tourette Syndrome Phase 2b trial.
Via
Benzinga
Exposures
Product Safety
US Stocks Open Higher; Dow Jumps Over 200 Points
January 06, 2025
Via
Benzinga
Topics
Stocks
Exposures
US Equities
SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment
January 06, 2025
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder
December 31, 2024
From
SciSparc Ltd
Via
GlobeNewswire
S&P 500 Edges Lower, SciSparc Shares Surge
December 26, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Dow Gains 50 Points, SEALSQ Shares Plummet
December 26, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Nasdaq Dips Over 100 Points, US Initial Jobless Claims Fall
December 26, 2024
Via
Benzinga
SciSparc Shares Skyrocket With AutoMax's First JAC Motors Shipment
December 26, 2024
SciSparc Ltd. shares are soaring after its merger-bound AutoMax Motors received its first shipment of JAC vehicles. The shipment positions AutoMax to begin marketing and sales activities for JAC Motors...
Via
Benzinga
Why Zoomcar Shares Are Trading Higher By Around 142%; Here Are 20 Stocks Moving Premarket
December 26, 2024
Via
Benzinga
SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation
December 26, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company
December 16, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Pharma Company Gets FDA Green Light For Next Phase Trial For Tourette Syndrome
September 30, 2024
SciSparc secures FDA approval for Phase IIb clinical trial of SCI-110, targeting unmet needs in Tourette Syndrome, Global trial begins soon.
Via
Benzinga
Exposures
Product Safety
SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment
September 30, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX
September 26, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment
September 23, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment
September 18, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Clearmind Medicine Files International Patent For Ibogaine Combination Therapy
September 17, 2024
Clearmind Medicine filed an international patent for a treatment that aims to enhance addiction treatment safety and efficacy.
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
September 17, 2024
Via
Benzinga
SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy
September 16, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax’s Direct Import Agreement with Major Chinese Vehicle Manufacturer
September 11, 2024
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
September 06, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
September 06, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination
August 29, 2024
From
SciSparc Ltd
Via
GlobeNewswire
Why Affirm Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
August 29, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.